



FOR RELEASE 3:00 P.M. CENTRAL
WEDNESDAY, APRIL 26, 2006
Contact: John K. Bakewell
(901) 867-4527

Wright Medical Group, Inc. Reports Results for First Quarter Ended March 31, 2006

First Quarter Sales and Adjusted Earnings Exceed Company's Outlook Range

ARLINGTON, TN – April 26, 2006 - Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics, today reported financial results for its first quarter ended March 31, 2006.

Net sales totaled \$86.3 million during the first quarter ended March 31, 2006, representing a 4% increase over net sales of \$82.6 million during the first quarter of 2005. Excluding the impact of foreign currency, net sales increased 7% during the first quarter. Net income for the first quarter of 2006 totaled \$2.3 million or \$0.07 per diluted share, including the after-tax effect of approximately \$3.4 million of non-cash stock-based compensation related to FASB Statement No. 123R. Excluding stock-based compensation, net income, as adjusted, totaled \$5.1 million, or \$0.14 per diluted share, for the first quarter of 2006. Net income for the first quarter of 2005 totaled \$7.3 million, or \$0.21 per diluted share. A reconciliation of GAAP to "as adjusted" results is included in the attached financial tables.

F. Barry Bays, Executive Chairman of the Board of Directors commented, "We are very pleased with the results of our first quarter relative to our established goals of restoring the predictability of our business model and returning the Company to its stated long-term financial performance objectives by the end of this year. During the first quarter, both our net sales and adjusted earnings performances exceeded the upper ends of their respective communicated outlook ranges. At the same time, consistent with our plan to further develop the capabilities of our business during 2006, we continued to make steady progress with our geographic market expansion initiatives and with our domestic field sales force specialization efforts. Although we expect and demand better performance from our business over the long run, the first quarter provided a solid start to a year where improving operations and positioning the Company for future growth are our top priorities."

Gary D. Henley, recently-appointed President and Chief Executive Officer commented, "Wright's fundamental business platform is well-developed and offers both the capability and scalability needed to support future growth initiatives while also enabling future operating leverage. Throughout 2006, we will remain focused on creating opportunities for future sales growth acceleration, improving the overall operating efficiency and cost-effectiveness of our existing business platform and positioning the business for a return to its stated long-term financial objectives of low- to mid-teens annualized sales growth accompanied by improving operating profitability as we exit 2006 and begin 2007."

Sales Review

Globally, the Company experienced growth across all of its major product lines during the first quarter of 2006. Specifically, global net sales of the Company's extremity, hip, knee and biologics product lines increased by 16%, 4%, 2% and 1%, respectively, during the first quarter of 2006 when compared to the first quarter of 2005.

Domestic sales totaled \$53.5 million during the first quarter of 2006, representing an increase of 7% compared to prior year. First quarter domestic sales of the Company's extremity, hip, knee and biologics product lines reflected growth of 15%, 13%, 2% and 1%, respectively.

International sales, as reported, were \$32.8 million for both the first quarter of 2006 and the first quarter of 2005. The Company's international sales results included an unfavorable foreign currency impact totaling approximately \$2.1 million during the first quarter of 2006. Excluding the impact of foreign currency, international sales increased by 6% during the first quarter of 2006.

Outlook

The Company's earnings targets, as communicated in the guidance ranges stated below for the full year 2006 and the second quarter of 2006, exclude the effect of possible future acquisitions, other material future business developments, and the impact of expensing non-cash stock-based compensation pursuant to FASB Statement No. 123R.

The Company has increased the lower end of its previously-communicated sales target for the full year 2006 for a revised target range of \$334 million to \$340 million, representing an annual growth objective of approximately 5% to 7%, and has upwardly revised its previously-communicated earnings per share outlook, for a revised target range of \$0.56 to \$0.61 per diluted share for 2006, as adjusted. The Company continues to anticipate a return to its targeted financial profile of low- to mid-teens annualized sales growth accompanied by improving operating profitability by the fourth quarter of 2006.

The Company's anticipated targets for the second quarter of 2006 for net sales are in the range of \$84.5 million to \$86.5 million, representing a sales growth objective of 2% to 5% for the quarter, with earnings per share results ranging from \$0.11 to \$0.13 per diluted share, as adjusted.

As noted above, the Company's financial targets exclude the impact of non-cash stock-based compensation charges associated with FASB Statement No. 123R. While the amount of such non-cash charges will vary depending upon a number of factors, both within and beyond the Company's control, the Company currently estimates that the after-tax impact of stock-based compensation will range from \$0.34 to \$0.36 per diluted share for the full year 2006 and \$0.09 to \$0.10 per diluted share for the second quarter of 2006.

The Company's anticipated targets for net sales and earnings per share are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated targets. The anticipated targets are not predictions of the Company's actual performance. See the cautionary information about forward-looking statements in the "Safe-Harbor Statement" section of this press release.

Conference Call

As previously announced, the Company will host a conference call starting at 3:30 p.m. (Central Time) today. The live dial-in number for the call is 800-289-0533 (domestic) or 913-981-5525 (international). To access a simultaneous webcast of the conference call via the internet, go to the "Corporate – Investor Information" section of the Company's website located at www.wmt.com. A replay of the conference call by telephone will be available starting at 7:30 p.m. (Central Time) today and continuing until 12:00 a.m. (Central Time) on May 3, 2006. To hear this replay, dial 888-203-1112 (domestic) or 719-457-0820 (international) and enter the registration number 2368422. A replay of the conference call will also be available via the internet starting today and continuing for at least 12 months. To access a replay of the conference call via the internet, go to the "Corporate – Investor Information – Audio Archives" section of the Company's website located at www.wmt.com.

The conference call may include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release or otherwise available in the “Corporate – Investor Information – Supplemental Financial Information” section of the Company's website located at www.wmt.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as net sales, excluding the impact of foreign currency, gross profit, as adjusted, operating income, as adjusted, net income, as adjusted and net income, as adjusted, per diluted share. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. The measures exclude such items as business development activities, including purchased in-process research and development, the financial impact of significant litigation, and non-cash stock-based expense, all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe-Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends. The Company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including the factors discussed in the Company's filings with the Securities and Exchange Commission (including the Company's annual report on Form 10-K for the year ended December 31, 2005 under the heading, “Risk Factors”), which could cause the Company's actual results to materially differ from those described in the forward-looking statements. Although the Company believes that the forward-looking statements are accurate, there can be no assurance that any forward-looking statement will prove to be accurate. A forward-looking statement should not be regarded as a representation by the Company that the results described therein will be achieved. The Company wishes to caution readers not to place undue reliance on any forward-looking statement. The forward-looking statements are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statement after this date.

Wright Medical Group, Inc. is a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics. The Company has been in business for more than 50 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company's website at www.wmt.com.

--Tables Follow--

Wright Medical Group, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2006	March 31, 2005
Net sales	\$ 86,256	\$ 82,601
Cost of sales	23,393	22,788
Gross profit	62,863	59,813
Operating expenses:		
Selling, general and administrative	49,486	41,869
Research and development	7,343	4,897
Amortization of intangible assets	1,146	1,059
Total operating expenses	57,975	47,825
Operating income	4,888	11,988
Interest expense, net	(250)	90
Other expense, net	124	174
Income before income taxes	5,014	11,724
Provision for income taxes	2,705	4,455
Net income	\$ 2,309	\$ 7,269
Net income per share, basic	\$ 0.07	\$ 0.21
Net income per share, diluted	\$ 0.07	\$ 0.21
Weighted-average number of common shares outstanding, basic	34,198	33,875
Weighted-average number of common shares outstanding, diluted	35,177	35,201

Wright Medical Group, Inc.
Consolidated Sales Analysis
(dollars in thousands--unaudited)

	Three Months Ended		
	March 31, 2006	March 31, 2005	% change
Geographic			
Domestic	\$ 53,457	\$ 49,762	7.4%
International	32,799	32,839	(0.1%)
Total net sales	\$ 86,256	\$ 82,601	4.4%
Product Line			
Hip products	\$ 30,380	\$ 29,170	4.1%
Knee products	25,273	24,806	1.9%
Biologics products	15,636	15,413	1.4%
Extremity products	11,420	9,847	16.0%
Other	3,547	3,365	5.4%
Total net sales	\$ 86,256	\$ 82,601	4.4%

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended March 31, 2006	
	International Net Sales	Total Net Sales
Net sales, as reported	\$ 32,799	\$ 86,256
Currency impact as compared to prior period	2,139	2,139
Net sales, excluding the impact of foreign currency	<u>\$ 34,938</u>	<u>\$ 88,395</u>

Wright Medical Group, Inc.
Reconciliation of Non-GAAP Results of Operations
(in thousands, except per share data--unaudited)

	Three Months Ended March 31, 2006			Three Months Ended March 31, 2005		
	As Reported	Non-GAAP Adjust- ments (a)	As Adjusted	As Reported	Non-GAAP Adjust- ments (a)	As Adjusted
Net sales	\$ 86,256	\$ -	\$ 86,256	\$ 82,601	\$ -	\$ 82,601
Cost of sales	23,393	(66) (b)	23,327	22,788	(11) (b)	22,777
Gross profit	62,863	66	62,929	59,813	11	59,824
Operating expenses:						
Selling, general and administrative	49,486	(2,733) (b)	46,753	41,869	(201) (b)	41,668
Research and development	7,343	(577) (b)	6,766	4,897	-	4,897
Amortization of intangible assets	1,146	-	1,146	1,059	-	1,059
Total operating expenses	57,975	(3,310)	54,665	47,825	(201)	47,624
Operating income	4,888	3,376	8,264	11,988	212	12,200
Interest (income) expense, net	(250)	-	(250)	90	-	90
Other expense (income), net	124	-	124	174	-	174
Income before income taxes	5,014	3,376	8,390	11,724	212	11,936
Provision for income taxes	2,705	620 (c)	3,325	4,455	84 (c)	4,539
Net income	<u>\$ 2,309</u>	<u>\$ 2,756</u>	<u>\$ 5,065</u>	<u>\$ 7,269</u>	<u>\$ 128</u>	<u>\$ 7,397</u>
Net income per share, basic	<u>\$ 0.07</u>	<u>\$ 0.08</u>	<u>\$ 0.15</u>	<u>\$ 0.21</u>	<u>\$ 0.01</u>	<u>\$ 0.22</u>
Net income per share, diluted	<u>\$ 0.07</u>	<u>\$ 0.07</u>	<u>\$ 0.14</u>	<u>\$ 0.21</u>	<u>\$ 0.00</u>	<u>\$ 0.21</u>
Weighted-average number of common shares outstanding, basic	<u>34,198</u>	<u>-</u>	<u>34,198</u>	<u>33,875</u>	<u>-</u>	<u>33,875</u>
Weighted-average number of common shares outstanding, diluted	<u>35,177</u>	<u>(24)</u>	<u>35,153</u>	<u>35,201</u>	<u>-</u>	<u>35,201</u>

(a) These Non-GAAP adjustments reconcile the Company's GAAP results of operations to its as adjusted results of operations.

(b) These adjustments reflect non-cash stock based compensation.

(c) These adjustments reflect the tax impact of the above noted non-GAAP adjustments.

Wright Medical Group, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands--unaudited)

	March 31, 2006	December 31, 2005
Assets		
Current assets:		
Cash and cash equivalents	\$ 59,986	\$ 51,277
Marketable securities	24,100	25,000
Accounts receivable, net	64,236	61,729
Inventories	85,908	82,381
Prepaid expenses and other current assets	34,794	39,994
Total current assets	<u>269,024</u>	<u>260,381</u>
Property, plant and equipment, net	83,162	81,206
Intangible assets, net	19,752	20,553
Other assets	11,089	9,670
Total assets	<u>\$ 383,027</u>	<u>\$ 371,810</u>
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 14,859	\$ 13,572
Accrued expenses and other current liabilities	47,920	45,055
Current portion of long-term obligations	5,246	5,628
Total current liabilities	<u>68,025</u>	<u>64,255</u>
Long-term obligations	1,331	1,728
Other liabilities	13,967	13,819
Total liabilities	<u>83,323</u>	<u>79,802</u>
Stockholders' equity	299,704	292,008
Total liabilities and stockholders' equity	<u>\$ 383,027</u>	<u>\$ 371,810</u>

#####